August 2018-Global Life Science Business Partnering - News & Updates
Highlights for August 2018
- Glenmark partners with Harbour BioMed to develop, manufacture and commercialize the former’s novel oncology molecule (GBR 1302), for China.
- Novo Nordisk inks an agreement with Signet Chemical Corporation for the distribution of its pharmaceutical range of quaternary ammonium compounds (FEF® Quats) in India, Bangladesh and Sri Lanka.
- Glenmark forms JV with True North for pain management, orthopaedic business.
- Panacea Biotec enters into tripartite agreement with Natco and Breckenridge for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA.
- Glenmark inks licensing pact for marketing Tiotropium Bromide DPI in Europe.
- Zydus Cadila to buy majority stake in Tano Capital-backed Windlas Biotech's unit.
- Auxly Cannabis to acquire CRO KGK for US$12.3 million in cash, stock deal.
- Emergent BioSolutions agrees to buy Narcan spray maker Adapt Pharma for US$735 million.
- Canada’s Altasciences has penned a new deal that sees it snap up the preclinical testing business of SNBL USA.
- Almirall buys Allergan's US dermatology portfolio for US$650 million.
- Sarepta builds in gene therapy with US$30 million Lacerta deal.
- Regeneron and Bluebird Bio collaborate on T-cells in US$100 million deal.
Updates at Aagami:
- Aagami gets a repeat assignment from a US based client for preparing Investor Friendly Pitch and Presentation.
- Several discussions move to Term sheet level for multiple client projects.
- Three Pharma/Biotech companies of India approach Aagami for Cross-border partnering support.
- Linda Pullan and Elizabeth Song move from Aagami partner consultant role to Strategic collaboration on as-needed basis for serving our clients better.
- Aagami registers for BIO-EUROPE 2018 (Copenhagen, Denmark, November 5–7, 2018).
- Aagami CEO embarks on a two week business trip to South Korea and Japan from Sep 01-14.